Skip to content

Efficacy and safety of indobufen, aspirin, cilostazol and clopidogrel in the treatment of ischemic stroke: a single center, retrospective study

Efficacy and safety of indobufen, aspirin, cilostazol and clopidogrel in the treatment of ischemic stroke: a single center, retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125768
Enrollment
Unknown
Registered
2026-05-31
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Aspirin group:None
Cilostazol group:None
Clopidogrel group:None

Sponsors

Southern Medical University Southern Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. For patients who visited the Neurology Department of Southern Hospital of Southern Medical University from January 2020 to February 2025: (1) Age >= 18; (2) Patients diagnosed with ischemic stroke in accordance with the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023"; (3) Within 7 days after discharge, receive one of indobufen, aspirin, cilostazol or clopidogrel, or a combination of two of them (as a dual preventive regimen); (4) The patient has been out of contact with the hospital for more than one year. 2. For patients who visited the Neurology Department of Nanfang Hospital of Southern Medical University from March 2025 to December 2025: (1) Age >= 18; (2) Patients diagnosed with ischemic stroke in accordance with the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023"; (3) Within 7 days after discharge, receive one of indobufen, aspirin, cilostazol or clopidogrel, or a combination of two of them (as a dual preventive regimen); (4) With follow-up records for one year after the initial treatment; (5) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Long term use of oral anticoagulants (such as warfarin, dabigatran, rivaroxaban, etc.) has been required at baseline; 2. History of hemorrhagic stroke and active bleeding; 3. Severe liver and kidney dysfunction (such as AST/ALT > 3 times the upper limit of normal value, or estimated glomerular filtration rate eGFR < 30 mL/min/1.73 m^2), end-stage disease, intracranial tumor or intracranial infection.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale;

Secondary

MeasureTime frame
Glasgow Coma Scale score;state of existence;Essen score;Barthel Index;Medication usage;National Institute of Health stroke scale;

Countries

China

Contacts

Public ContactJia Yin

Southern Medical University Southern Hospital

jiajiayin@139.com+86 138 0296 4883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026